Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Deutsche Bank downgrades SCHOTT Pharma to hold, target raised to €25

Deutsche Bank Research has downgraded SCHOTT Pharma from "Buy" to "Hold", but raised the price target from €23 to €25. Analyst Falko Friedrichs cites progress in meeting expectations and rates the medium-term outlook as attractive, but after the almost 70% price rise since the start of the year sees little further upside. » More on finanzen.net
Schott CEO Torsten Derr to step down at end of October, Stefan Brandl named successor

Torsten Derr will leave specialty glass maker Schott on October 31 for personal and family reasons after less than two years in office. His successor will be Stefan Brandl, current CEO of Dräxlmaier and a member of Schott’s supervisory board, who will assume the role on November 1. Schott employs around 17,400 people and produces, among other things, glass products for household appliances, data glasses and the semiconductor industry. » More on manager-magazin.de
Schott Pharma shares fall after rise to yearly high despite JPMorgan upgrade

Schott Pharma’s shares jumped 5.5% at the market open to their highest level in over a year, but later fell back and were last up 1.6% at €22.95. The rally for the current year is around 52%. JPMorgan initiated coverage with an "Overweight" rating and a €27.10 price target, seeing Schott as a beneficiary of structural trends and forecasting average annual earnings growth potential of 14% through 2029. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, SCHOTT Pharma has already paid €0.18 in dividends. The last payout was in February.

Financials

In the last quarter, SCHOTT Pharma had revenue of €281.76m and net profit of €38.83m

(EUR)	June 2026	YoY
Revenue	281.76m	9.87%
Gross profit	86.38m	10.11%
Net profit	38.83m	14.78%
EBITDA	71.14m	16.09%

Fundamentals

Metric	Value
Market capitalization	€3.8bn
Number of shares	150.61m
52-week high/low	€26.10 - €12.62
Dividend yield	0.72%
Dividends TTM	€0.18
Beta	0.99
P/E ratio	27.69
PEG ratio	-3.88
P/B ratio	3.78
P/S ratio	3.73

Company profile

SCHOTT Pharma AG & Co. KGaA develops, produces, and sells drug containment solutions and delivery systems for injectable drugs to the pharmaceutical and biotechnology industries worldwide. The company offers polymer and glass syringes, ampoules, vials, and cartridges. Its syringe products include syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; and SCHOTT TOPPAC unique, a polymer container. The company's cartridge products comprise cartriQ, a pharmaceutical glass cartridge for peptide and protein-based injectables; cartriQ Large Volume, a pharmaceutical glass cartridge for large-volume injectables; Cartridges Double Chamber, a pharmaceutical glass cartridge for lyophilized drugs; Cartridges Break Resistant, a pharmaceutical glass cartridge; and TopLine and StandardLine cartridges. Its vial products include adaptiQ, a pharmaceutical glass vial for injectables; EVERIC pure, a pharmaceutical glass vial for unmatched drug stability; EVERIC care, a pharmaceutical glass vial for a pH range; EVERIC strong & smooth, a pharmaceutical glass vial for the filling line performance; SCHOTT Type I plus, a pharmaceutical glass vial for drug formulations; SCHOTT TopLyo, a pharmaceutical glass vial to avoid fogging for lyophilized drugs; and TopLine and StandardLine vials. Its ampoule products comprise Ampoules easyOPC, a pharmaceutical glass ampoule for ampoule opening; Ampoules Anti-Counterfeiting, a pharmaceutical glass ampoule for protection against drug counterfeiting; and StandardLine ampoules. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.

Name	SCHOTT Pharma
CEO	Christian Mias
Headquarters	Mainz, rp Germany
Website	schott-pharma.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	26/09/2023
Employees	5,002